Trametinib is another MEK inhibitor approved for BRAF V600-mutant melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and has shown activity in MAPK-driven histiocytic neoplasms, including hairy cell leukemia. Here, MAP2K7 is linked to melanoma.